Mirum Pharmaceuticals

MIRM

Market cap $5.89B

FOSTER CITY, Calif.--(BUSINESS WIRE)--Mirum Pharmaceuticals to Announce First Quarter 2026 Financial Results and Host Conference Call on May 6, 2026.

Mirum Pharmaceuticals (MIRM) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

FOSTER CITY, Calif.--(BUSINESS WIRE)--Mirum Pharmaceuticals Announces Primary Endpoint Met in Phase 2b Portion of the AZURE-1 Study of Brelovitug in Chronic Hepatitis Delta Virus.

Vertex Pharmaceuticals has shown steady financial growth. Mirum Pharmaceuticals is getting closer to being profitable.

MIRM heads into Q1 earnings with Livmarli sales in focus after 69% year-over-year growth in 2025. Bile acid products broaden revenue momentum.

FOSTER CITY, Calif.--(BUSINESS WIRE)--Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4).

Mirum Pharmaceuticals already markets three therapies. The company plans to report four pivotal readouts from clinical studies over the next 18 months.

STOCKHOLM, SE / ACCESS Newswire / April 9, 2026 / Egetis Therapeutics AB (publ) ("Egetis" or the "Company") (STO:EGTX), today announced the appointment of Tiago Nunes, MD, PhD, as Chief Medical Officer (CMO), effective May 1, 2026. Tiago Nunes is an experienced clinical development leader, with significant expertise advancing rare disease therapeutics through regulatory approval and launch, having most recently served as Senior Vice President, Clinical Development at Mirum Pharmaceuticals (NASDAQ: MIRM).

Mirum Pharmaceuticals (MIRM) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.

Mirum Pharmaceuticals (MIRM) reported earnings 30 days ago. What's next for the stock?